Evidence map›Paper›PMID 41171869›Full record

ArticleDiabetes2026

Dual-Input Regulation of β-Cell Proliferation by ATF6α and Glucose via E2F1.

Huguet V Landa-Galvan, Thalia A Castro, Jahi J Noel, Gabriel Avila Llamas, Rohit B Sharma, Laura C Alonso

Abstract read
In one paragraph

Article in Diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huguet V Landa-GalvanDivision of Endocrinology, Diabetes and Metabolism and the Joan and Sanford I. Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY.
Thalia A CastroDivision of Endocrinology, Diabetes and Metabolism and the Joan and Sanford I. Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY.
Jahi J NoelDivision of Endocrinology, Diabetes and Metabolism and the Joan and Sanford I. Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY.
Gabriel Avila LlamasDivision of Endocrinology, Diabetes and Metabolism and the Joan and Sanford I. Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY.
Rohit B SharmaDivision of Endocrinology, Diabetes and Metabolism and the Joan and Sanford I. Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY.
Laura C AlonsoDivision of Endocrinology, Diabetes and Metabolism and the Joan and Sanford I. Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY.ORCID 0000-0001-5056-8970

Funding

Stable Isotope and Metabolomics CoreP60DK020541 · NIDDK · YESHIVA UNIVERSITY · PI PESSIN, JEFFREY E. · 1986 to 2014
$29.8M
Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY E. PESSIN · 2015 to 2026
$27.7M
Integrated Islet Distribution Program (U24) - 2021U24DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Carmella Evans-Molina, Joyce Carol Niland · 2021 to 2026
$17.8M
Role of Polyamines and Hypusine in Nutrient-Induced Beta-Cell Growth and ReplicationR01DK124906 · NIDDK · UNIVERSITY OF CHICAGO · PI Raghavendra G Mirmira · 2020 to 2026
$4.0M
Benefits and harms of activating ATF6 in beta cellsR01DK135304 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI Laura C Alonso · 2023 to 2026
$1.8M
Role of GRP78 in beta cell adaptation in obesity and diabetesR01DK113300 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI ALONSO, LAURA C · 2018 to 2021
$1.7M
ATF6 and the Beta CellR01DK114686 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI ALONSO, LAURA C · 2017 to 2019
$1.5M
Forced Activation of ATF6 Drives Pancreatic Beta Cell DysfunctionF31DK136225 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI Andrew Rappa · 2024 to 2026
$149k
City of Hope, NIH U24DK098085Joan and Sanford I. Weill Center for Metabolic HealthNIDDK-funded Integrated Islet Distribution Program (IIDP)NIDDK NIH HHS F31 DK136225NIDDK NIH HHS P30 DK020541NIDDK NIH HHS P60 DK020541NIDDK NIH HHS R01 DK113300NIDDK NIH HHS R01 DK114686NIDDK NIH HHS R01 DK124906NIDDK NIH HHS R01 DK135304NIDDK NIH HHS U24 DK098085NIH HHS F31DK136225NIH HHS R01DK113300NIH HHS R01DK114686NIH HHS R01DK124906NIH HHS R01DK135304NIH/NIDDK DK020541NIH/NIDDK P-30
6 · The paper itself

Abstract

Finding ways to increase β-cell mass is a key goal of diabetes research. During elevated insulin demand, β-cells turn on endoplasmic reticulum (ER) stress response pathways, and some β-cells enter the cell cycle. ER stress response protein activating transcription factor 6 (ATF6α) induces β-cell proliferation, but only in high glucose. The mechanism by which ATF6α increases proliferation, and the reasons for glucose dependence, remain unknown. Here we show that ATF6α activation in mouse and human islet cells increases expression of E2F1, a key cell cycle driver. E2F1 was required for ATF6α-induced proliferation in high glucose. However, E2F1 remained inactive in normal glucose, possibly because retinoblastoma (Rb), a direct E2F1 inhibitor, was in its dephosphorylated, active state. Indeed, inducing Rb phosphorylation by overexpressing cyclin-dependent kinase 4 (CDK4) allowed ATF6α to increase E2F1 activity and β-cell proliferation in normal glucose. E2F1 expression increased in an ATF6α-dependent manner during generalized ER stress by thapsigargin treatment. Importantly, in human β-cells, ATF6α failed to synergize with high glucose to induce proliferation, but the synergy was rescued by adding back CDK6. Taken together, this study establishes a new dual-input β-cell proliferation regulatory mechanism integrating ER load with current glycemic conditions via CDK4/6, in which Rb phosphorylation serves as a glucose sensor that permits ATF6α-driven proliferation. ARTICLE HIGHLIGHTS: Endoplasmic reticulum stress response mediator activating transcription factor 6 (ATF6α) increases pancreatic β-cell proliferation in a glucose-dependent manner, but the mechanism remains unknown. ATF6α activation upregulated mRNA and protein expression of E2F1, a key G1/S phase transition regulator; however, E2F1 activity only increased in high glucose. Glucose dependence of E2F1 activity was mediated by cyclin-dependent kinase 4/6 phosphorylation of retinoblastoma (Rb) protein, derepressing E2F1 in high glucose. Generalized endoplasmic reticulum stressor thapsigargin increased E2F1 abundance in an ATF6-dependent manner. ATF6α increased E2F1 expression in human β-cells and increased human β-cell proliferation when cyclin-dependent kinase 6 (CDK6) was coexpressed.

Indexed as

Activating Transcription Factor 6Cell ProliferationE2F1 Transcription FactorGlucoseInsulin-Secreting CellsAnimalsCyclin-Dependent Kinase 4Endoplasmic Reticulum StressHumansMicePhosphorylationRetinoblastoma ProteinThapsigarginActivating Transcription Factor 6ATF6 protein, humanAtf6 protein, mouseCyclin-Dependent Kinase 4E2F1 protein, humanE2f1 protein, mouseE2F1 Transcription FactorGlucoseRetinoblastoma ProteinThapsigargin

Identifiers

PMID41171869
PMCPMC12622758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.